NCI-2023-03637

A 2-Part Open-Label Phase I Study of TAVO412 in Patients with Advanced or Metastatic Solid Tumors who progressed on prior approved standard of care therapy

This Phase I study is looking at a new medicine called TAVO412 in people with advanced or metastatic solid tumors who haven't responded to previous standard treatments. It's an open-label study, which means everyone knows what treatment they're getting. The goal is to see if TAVO412 is safe and if it helps treat cancer that hasn't responded to other treatments.

Phase I study: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

metastatic: cancer that has spread from its original location or organ to other parts of the body.

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05548634

Clinical Trial Site: Sinai

To see all available clinical trials click here.